LETTERS TO THE EDITOR

House Dust Mite Allergy Immunotherapy Tablet
Wiwanitkit V
Joseph Ayo Babalola University, Ikeji-Arakeji, Nigeria

Key words: House dust mite. Allergy. Immunotherapy. Tablet.

To the Editor:
A very interesting report was recently published on the orodispersible house dust mite allergy sublingual immunotherapy (HDM-SLIT) tablet in which Corzo et al [1] noted that “doses up to 12 development units of HDM SLIT-tablet were tolerated in the selected populations, and thus are suitable for further clinical investigations in adults and children with HDM respiratory allergic disease.” HDM allergy immunotherapy, however, is a major challenge in allergology. The HDM SLIT-tablet is a new drug that has proven useful in several allergic diseases as well as asthma [2,3]. Some authors, however, have offered a more measured opinion on the benefits of the tablet. Pham-Thi et al [4], for example, noted that SLIT with tablets of HDM extract “does not provide additional benefit, despite a significant reduction in allergic response to HDM.” In addition, because the HDM SLIT-tablet is relatively new, data on its short- and long-term adverse effects need to be closely monitored.

References

Manuscript received September 8, 2014; accepted for publication, October 9, 2014.

Viroj Wiwanitkit
Wiwanitkit House
Bangkhae, Bangkok
Thailand 10160
E-mail: wviroj@yahoo.com